Portage Biotech (PRTG) Stock Forecast, Price Target & Predictions
PRTG Stock Forecast
Portage Biotech stock forecast is as follows: an average price target of $19.50 (represents a 447.75% upside from PRTG’s last price of $3.56) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
PRTG Price Target
The average price target for Portage Biotech (PRTG) is $19.50 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $18.00. This represents a potential 447.75% upside from PRTG's last price of $3.56.
PRTG Analyst Ratings
According to 1 Wall Street analysts, Portage Biotech's rating consensus is 'Buy'. The analyst rating breakdown for PRTG stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Portage Biotech Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 01, 2022 | - | H.C. Wainwright | $21.00 | $5.88 | 257.14% | 489.89% |
| Nov 30, 2022 | - | Oppenheimer | $18.00 | $5.96 | 202.01% | 405.62% |
The latest Portage Biotech stock forecast, released on Dec 01, 2022 by H.C. Wainwright company, set a price target of $21.00, which represents a 257.14% increase from the stock price at the time of the forecast ($5.88), and a 489.89% increase from PRTG last price ($3.56).
Portage Biotech Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $3.56 | $3.56 | $3.56 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Portage Biotech stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Portage Biotech's last price of $3.56. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 30, 2022 | Oppenheimer | Outperform | Outperform | Hold |
Portage Biotech's last stock rating was published by Oppenheimer on Nov 30, 2022. The company gave PRTG a "Outperform" rating, the same as its previous rate.
Portage Biotech Financial Forecast
Portage Biotech Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|
| Revenue | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| # Analysts | - | - | 1 |
| Surprise % | - | - | - |
Portage Biotech's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PRTG's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Portage Biotech EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|
| # Analysts | - | - | 1 |
| EBITDA | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
undefined analysts predict PRTG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Portage Biotech's previous annual EBITDA (undefined) of $NaN.
Portage Biotech Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|
| # Analysts | - | - | 1 |
| Net Income | - | - | - |
| Avg Forecast | $1.62M | $1.41M | $-87.05M |
| High Forecast | $1.62M | $1.41M | $-83.09M |
| Low Forecast | $1.62M | $1.41M | $-87.05M |
| Surprise % | - | - | - |
Portage Biotech's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRTG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Portage Biotech SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|
| # Analysts | - | - | 1 |
| SG&A | - | - | - |
| Avg Forecast | - | - | - |
| High Forecast | - | - | - |
| Low Forecast | - | - | - |
| Surprise % | - | - | - |
Portage Biotech's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PRTG last annual SG&A of $NaN (undefined).
Portage Biotech EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | |
|---|---|---|---|
| # Analysts | - | - | 1 |
| EPS | - | - | - |
| Avg Forecast | $1.54 | $1.34 | $-4.40 |
| High Forecast | $1.54 | $1.34 | $-4.20 |
| Low Forecast | $1.54 | $1.34 | $-4.40 |
| Surprise % | - | - | - |
According to undefined Wall Street analysts, Portage Biotech's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRTG previous annual EPS of $NaN (undefined).
Portage Biotech Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| FREQ | Korro Bio | $0.30 | $7.00 | 2233.33% | Buy |
| CUE | Cue Biopharma | $0.59 | $5.00 | 747.46% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| PRTG | Portage Biotech | $3.56 | $19.50 | 447.75% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| ARVN | Arvinas | $25.05 | $75.36 | 200.84% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| FENC | Fennec Pharmaceuticals | $5.47 | $15.75 | 187.93% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| HRMY | Harmony Biosciences | $38.91 | $50.67 | 30.22% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| JANX | Janux Therapeutics | $50.01 | $59.25 | 18.48% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| VECT | VectivBio | $16.87 | $18.00 | 6.70% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
PRTG Forecast FAQ
Is Portage Biotech a good buy?
Yes, according to 1 Wall Street analysts, Portage Biotech (PRTG) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of PRTG's total ratings.
What is PRTG's price target?
Portage Biotech (PRTG) average price target is $19.5 with a range of $18 to $21, implying a 447.75% from its last price of $3.56. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Portage Biotech stock go up soon?
According to Wall Street analysts' prediction for PRTG stock, the company can go up by 447.75% (from the last price of $3.56 to the average price target of $19.5), up by 489.89% based on the highest stock price target, and up by 405.62% based on the lowest stock price target.
Can Portage Biotech stock reach $5?
PRTG's average twelve months analyst stock price target of $19.5 supports the claim that Portage Biotech can reach $5 in the near future.
What are Portage Biotech's analysts' financial forecasts?
PRTG's analysts financial forecasts for the fiscal year (Mar 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-87.05M (high $-83.093M, low $-87.05M), average SG&A $0 (high $0, low $0), and average EPS is $-4.4 (high $-4.2, low $-4.4).